In recent years, more and more countries have begun to recognize and adopt traditional Chinese medicine, which provides a broad market space for the development of the traditional Chinese medicine industry. As a leading enterprise of innovative traditional Chinese medicine, Yiling Pharmaceutical has begun to continuously strengthen brand building, and continues to enrich the product matrix with strong scientific research and innovation strength, and its efficacy has won unanimous praise from consumers at home and abroad, which has greatly promoted the growth of Yiling's performance.
Under the guidance of the innovation and development strategy of "market leader and science and technology driven", Yiling Pharmaceutical has established a five-in-one innovative development model of "theory, clinical, scientific research, teaching and industry", that is, combining the theoretical innovation of network disease with modern high-tech R&D and production of innovative traditional Chinese medicine, so as to promote the high-quality development of the traditional Chinese medicine industry. At present, Yiling Pharmaceutical has innovation platforms such as the National Enterprise Technology Center, the State Key Laboratory, and the National and Local Joint Engineering Laboratory, with 2,000 scientific research personnel, and has independently developed more than 10 innovative traditional Chinese medicines, covering major diseases such as cardiovascular and cerebrovascular diseases, respiratory diseases, and tumors. Among them, the field of cardiovascular and cerebrovascular and cold and respiratory diseases has become the main driving force for the growth of Yiling's performance.
Not long ago, the Journal of the American Medical Association (JAMA), the world's top medical journal, published a significant traditional Chinese medicine study, "Clinical Efficacy of Acute Myocardial Infarction of China Tongxinluo** - CTS-AMI Clinical Randomized Study". The results of this study showed that Tongxinluo can significantly improve the clinical prognosis of patients with ST-elevation myocardial infarction (STMI) at 30 days and 1 year. This achievement not only marks the first time that traditional Chinese medicine has appeared in the top international medical journal, but also opens up a new increment for the growth of Yiling's performance.
In addition to these first-line varieties, Yiling Pharmaceutical has also launched a number of second-line varieties in the fields of mental system and anti-aging, and has achieved rapid expansion. At the 2nd Anti-Aging Conference of Traditional Chinese Medicine, the National Key R&D Program Project "Modernization of Traditional Chinese Medicine" key special project "Research on the Evaluation Technology and Integration Mechanism of Anti-aging of Traditional Chinese Medicine Guided by the Theory of Qi and Qi Spirit" was officially launched. This marks that the "weight value" of Yiling Pharmaceutical's anti-aging representative product Bazi Kidney Supplement Capsule in the company may be further improved in the future, and the company will also tilt more R&D and marketing resources to Bazi Kidney Supplement, which is expected to become a large variety of billions of yuan and continue to contribute to the growth of Yiling's performance.
In addition, the overseas registration of Yiling Pharmaceutical's innovative traditional Chinese medicine has begun as early as a few years ago, and the accumulation of more than ten years has also provided strong support for Yiling's "traditional Chinese medicine going overseas". At present, Yiling Pharmaceutical's patented innovative drugs such as Lianhua Qingwen Capsule, Tongxinluo Capsule, and Ginseng Song Yangxin Capsule have obtained registration approvals from more than 50 countries and regions, and the international registration of second-tier varieties such as Jinlida Granules, Xia Liqi Capsules, and Bazi Kidney Supplement Capsule is also accelerating. At the same time, the company also continued to increase investment in R&D, and in the four years from 2018 to 2022, the company's cumulative R&D expenses exceeded 3 billion yuan. Since 2023, the company's R&D expenses have further increased, and the R&D investment in the first three quarters has increased to 64.6 billion yuan, a year-on-year increase of 142%, laying a solid foundation for the growth of Yiling's performance.
It can be seen that Yiling's performance can achieve rapid growth, relying on strong scientific research and innovation strength, rich product matrix and active international market expansion. In the future, Yiling Pharmaceutical will continue to be guided by innovation, continue to drive the development trend of the Chinese medicine industry, and create more value for investors.